Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Companies

Ultragenyx Names Board Member

This article was originally published in Scrip

Executive Summary

Ultragenyx Pharmaceutical Inc. has appointed Sofinnova Ventures' executive partner Lars Ekman to its board as an independent director – effective since March 17, 2016. Prior to Sofinnova Ventures Ekman was president of R&D at Elan and previously he held various senior scientific and clinical roles at Pharmacia (acquired by Pfizer Inc.). Currently Ekman is chair of Amarin Corporation Plc., Sophiris Bio Inc., and Prothena Corporation Plc. and is a director of Spark Therapeutics Inc.

Table

View full table

Topics

Tags:
Companies
Latest Headlines

Analysis: Novo And Lilly Make Their Money Work

AstraZeneca’s Hot Streak Whets Investor Appetite For What’s Next

Sweden's InDex To Stay Afloat Thanks To Mystery Merger Partner

China Biotech Podcast: AACR, BIOSECURE European Perspectives

See All
UsernamePublicRestriction

Register

SC064837

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By